Pharmaceutical Commerce - April 2010 - (Page Cover1)

Business Strategies for Pharma/Bio Success APRIL 2010 Supply Chain | Logistics Brand Marketing | Communications New Study Sees Double-Digit Growth in Cold-Chain Services for Life Sciences Faster-than-average growth of biologics, more global trade to emerging countries, and widening regulatory requirements will propel the activity By Nicholas Basta 50 Years of Birth Control: Pharma Continues to Push for More Reproductive-Health Options Despite a gantlet of medical, institutional and ethical challenges, the industry has expanded patient choice By Suzanne Shelley A specialized area of life sciences distribution is undergoing a boom right now: temperature-controlled shipping of pharmaceuticals, vaccines, blood products and clinical trial materials (CTMs). It is well known that national and international regulatory authorities are looking more closely at how temperature-controlled pharma shipments are being managed. And it is equally well known that there is a growing pipeline of commercial and near-commercial biotech products that will often require close control of temperature. One of the latest to be approved—Dendreon’s highly anticipated prostate cancer “vaccine”—stands out for requiring temperature control both as a patient’s blood is conveyed to Dendreon’s processing centers, and as the treated product is returned for infusion. Looking at cold-chain biologics and pharmaceuticals alone, the dollar value of shipments was $147 billion in 2008, and projected to rise to $187 billion in 2011—a 27% growth rate, more than double that of overall biopharma growth (Fig. 1). These data come from a first-of-its-kind report, “Biopharma Cold Chain Sourcebook 2010,” published by Pharmaceutical Commerce. Blood plasma and sera has been projected (by Evaluate Pharma) as an $18-billion global industry, rising by 8% per year to 2014, or roughly $23 billion. Vaccines are projected to grow by an identical rate, from $20.6 billion in 2008 to about $26 billion in 2011. The CTM industry has been estimated at $50 billion worldwide, the majority of which is biotech-based. Even if this stays flat through 2011, the total value of cold chain product shipments for life sciences will be nearly $246 billion in 2011. Evidence of this growth can be seen in the number of air carriers, thirdparty logistics firms (3PLs) and packaging and storage firms bulking up their cold-chain services. UPS, FedEx, DB Schenker, DHL and most other life-sciences 3PLs now have specified cold-chain services (Pharmaceutical Commerce, Jan/Feb, p. 21); air carriers with specified cold-chain services include American Air Cargo, Continental, Delta, Cathay Pacific, Air Canada and Emirates SkyCargo; cold-chain unit-load devices (ULDs) such as Envirotainer and CSafe, and a growing number of packaging and instrumentation companies have joined the fray. continued on page 18 > Birth control is serious business for women, and it’s serious business for the drug industry. According to the Guttmacher Institute (New York), a nonprofit that focuses on reproductive health, over 62% of the 62 million women of childbearing age in the US use contraception. Since the typical woman wants only two children, most women will end up using contraception for roughly three decades to achieve that goal. Since Ortho Women’s Health & Urology (Titusville, NJ) first introduced “the Pill” in 1960, the field has become quite crowded, and today, nearly 30 different prescription birth control pills are available. Distinctions among similar products often become blurred in the minds of patients and physicians, and consumers are often challenged to truly understand the unique risk-reward profiles of competing options. continued on page 14 > Business Finance Site Selection 2010: Development Authorities Recalibrate Their Pitch as Biopharma Growth Slowly Rebounds Faced with fierce competition, dwindling budgets and intense pressure to create jobs, economic development authorities are reinventing their recruitment strategies to attract life sciences employers By Lena Anthony Cushman & Wakefield is finalizing a white paper examining the role the life sciences sector plays in influencing real estate growth. The paper, expected at the end of Q2, is a follow-up to a similar report released in 2007, which credited the life sciences sector as a growth driver. In the course of three years, and in the wake of the Great Recession, the commercial real estate firm’s message is now about the challenges facing the industry that are limiting its ability to expand. Chris Kinum, author of both reports and executive director of Cushman & Wakefield’s Global Life Science Practice (East Rutherford, NJ), points to a couple of major game-changers in the life sciences landscape. First, last year’s flurry of mergers between pharmaceutical companies, including Pfizer and Wyeth, Roche and Genentech, and continued on page 10 > What’s Inside Revenue Management for Complex Pricing Environment 12 Patient-Level Approach to Healthcare 21 Drug Delivery Technologies for Controlled Release MENDOTA, IL PERMIT 200 PRSRT STD US POSTAGE PAID 23

Table of Contents for the Digital Edition of Pharmaceutical Commerce - April 2010

Pharmaceutical Commerce - April 2010
Top News
Business & Finance
BrandMarketing | Communications
Supply Chain | Logistics
Information Technology
Packaging & Drug Delivery
Legal | Regulatory
Executive Training & Development
Editorial Index & Meetings

Pharmaceutical Commerce - April 2010